Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus by Moulaei, Tinoush et al.
Moulaei et al. Retrovirology  (2015) 12:6 
DOI 10.1186/s12977-014-0127-3RESEARCH Open AccessGriffithsin tandemers: flexible and potent lectin
inhibitors of the human immunodeficiency virus
Tinoush Moulaei1,2,3*, Kabamba B Alexandre1, Shilpa R Shenoy1,4, Joel R Meyerson5, Lauren RH Krumpe1,4,
Brian Constantine1, Jennifer Wilson1, Robert W Buckheit Jr.6, James B McMahon1, Sriram Subramaniam5,
Alexander Wlodawer2* and Barry R O’Keefe1*Abstract
Background: The lectin griffithsin (GRFT) is a potent antiviral agent capable of prevention and treatment of
infections caused by a number of enveloped viruses and is currently under development as an anti-HIV microbicide.
In addition to its broad antiviral activity, GRFT is stable at high temperature and at a broad pH range, displays little
toxicity and immunogenicity, and is amenable to large-scale manufacturing. Native GRFT is a domain-swapped
homodimer that binds to viral envelope glycoproteins and has displayed mid-picomolar activity in cell-based
anti-HIV assays. Previously, we have engineered and analyzed several monomeric forms of this lectin (mGRFT) with
anti-HIV EC50 values ranging up to 323 nM. Based on our previous analysis of mGRFT, we hypothesized that the
orientation and spacing of the carbohydrate binding domains GRFT were key to its antiviral activity.
Results: Here we present data on engineered tandem repeats of mGRFT (mGRFT tandemers) with antiviral
activity at concentrations as low as one picomolar in whole-cell anti-HIV assays. mGRFT tandemers were
analyzed thermodynamically, both individually and in complex with HIV-1 gp120. We also demonstrate by
dynamic light scattering and cryo-electron microscopy that mGRFT tandemers do not aggregate HIV virions.
This establishes that, although the intra-virion crosslinking of HIV envelope glycoproteins is likely integral
to their activity, the antiviral activity of these lectins is not due to virus aggregation caused by inter-virion
crosslinking.
Conclusions: The engineered tandemer constructs of mGRFT may provide novel and powerful agents for
prevention of infection by HIV and other enveloped viruses.
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The surface glycoproteins of enveloped viruses act as an-
chors for docking and fusion with the target cell’s mem-
brane [1]. These glycoproteins are the most prominent
features of the viral surface that can be recognized
within the host cellular background and are targeted
for antibody neutralization. Consequently, viruses have
evolved a number of strategies for shielding the spike
structures formed by their surface glycoproteins. These
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unless otherwise stated.structural features through conformational occlusion
and oligomerization [2,3], sequence hyper-variability, es-
pecially within loops that mask conserved epitopes [4],
and extensive posttranslational glycosylation [5].
N-linked carbohydrates compose approximately 50%
of the molecular weight of HIV gp120 [6]. This glycan
armor hides the underlying protein structures on one
face of gp120, whereas the epitopes on the other face of
gp120 are masked by the quaternary structure of the tri-
meric spike [7]. The effectiveness of glycans in this de-
fensive mechanism may in part hinge on the generally
weak interactions between proteins and carbohydrates
[8]. The glycan modifications of HIV Env are also essen-
tial for its folding and function [9,10]. Evolution of mu-
tations in the position and frequency of N-linked glycansl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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during the course of infection and appears to occur
within limits affected by immune evasion, efficient pro-
cessing, and access to receptor binding sites [11]. Logic-
ally, mu that would reduce the glycosylation levels of
HIV Env could affect viral processing and maturation,
leading to attenuated infectivity, as well as further ex-
posing the virus to the immune system. Therefore, tar-
geting this viral glycan shield may be an effective way of
combating HIV infection.
Lectins are small proteins that have evolved to bind
carbohydrates with high affinity and specificity. A num-
ber of lectins have been shown to display potent antiviral
activity [12]. Currently, the most potent reported anti-
HIV lectin is griffithsin (GRFT), an obligate domain-
swapped dimer in which each domain has jacalin-like
fold (Figure 1A) [13]. GRFT has anti-HIV EC50 of ~50
pM in cell-based assays [14] and exhibits synergistic ef-
fects against HIV in combination with other antiviral
agents [15-17]. Additionally, GRFT has been reported to
exhibit antiviral activity against the coronavirus respon-
sible for SARS [18,19], the hepatitis C virus [20], the
Japanese encephalitis virus [21], and the murine herpes
simplex virus type 2 [22]. There are a number of charac-
teristics that make GRFT an attractive candidate for devel-
opment as an antiviral therapeutic. GRFT is thermostable,
can survive in a wide range of conditions including those
found in the macaque vaginal environment, and exhibits
little or no toxicity and immunogenicity [23]. Subcutane-
ous administration of GRFT in rodent models has also
shown that this lectin accumulates to therapeutically ef-
fective levels in serum and plasma with minimal toxicity
[24]. Finally, low-cost, large-scale production of GRFT in
genetically modified tobacco plants has been demon-
strated [25].
We have previously determined the structures of unli-
ganded, native GRFT (Figure 1A) and its complexes withFigure 1 Structure and binding site orientation of dimeric GRFT and m
a domain-swapped dimer with two identical carbohydrate-binding domain
from each other. Obligate monomeric GRFT (B) was generated by the addition
flexibility of the hinge region resulted in the collapse of the swapped domain toa number of mono- and disaccharides [26-28]. In its na-
tive form GRFT is a rigid domain-swapped homodimer.
We also engineered several monomeric forms of GRFT
(mGRFT) (Figure 1B) and determined their structures,
including the structure of a complex with nonamannoside,
an analogue of Man9 that forms a common glycosylation
pattern found on HIV surface glycoproteins [29]. The
anti-HIV activity of mGRFT was approximately 1000-fold
lower than that of GRFT, although both the monomeric
and dimeric forms of this lectin have very similar
oligosaccharide-binding affinities. Therefore, we suggested
that the presence of two binding domains in native, di-
meric GRFT was important for its activity by allowing the
cross-linking of gp120-associated oligosaccharides. Such a
mechanism could also lead to the agglutination of HIV vi-
rions [30]. We hypothesized that providing more flexibility
and varying the distance between the two domains might
improve antiviral properties of the derivatives of GRFT.
Here we describe the design and characterization of four
new lectins constructed from two, three, and four tandem
repeats of mGRFT (mGRFT tandemers), which allow for
variation in the distance between the carbohydrate binding
domains and provide significant freedom to their orienta-
tion angle. These novel mGRFT tandemers displayed po-
tent anti-HIV activity down to a level of 1.0 pM and were
able to do so without engendering viral aggregation.
Results
Cloning, expression, and purification of mGRFT and GRFT
tandemers
The GRFT monomer 1GS-S ([30], PDB ID 3LL2, Figure 1B)
was chosen as the repeating unit in the design of
mGRFT tandemers, because the L2S mutation at its N
terminus rendered this monomer more susceptible to
proteolytic cleavage of its N-terminal affinity tag. All
further references to mGRFT in this work are to 1GS-S.
Schematic models of mGRFT tandemers constructedutations used to generate monomeric GRFT. Dimeric GRFT (A) is
s (circled in blue) separated by 50 Å and at a relative angle of ~160°
of Gly-Ser residues in the hinge region of wild-type GRFT. The enhanced
form an obligate monomer, mGRFT.
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Figure 2. The linker between each mGRFT domain was
chosen to be flexible and unstructured and consisted of
single and triple repeats of Gly-Thr-Gly. However, the
flexibility of the linker rendered all attempts at crystal-
lizing the tandemers unsuccessful. Purification of tande-
mers was performed largely as described previously
[30]. The relevant information for GRFT, mGRFT, and
the tandemers is listed in Table 1. The relative thermal
stability of the mGRFT tandemers was evaluated by dif-
ferential scanning calorimetry (Additional file 1: Table
S1). It was found that the mGRFT tandemers have simi-
lar melting temperatures to mGRFT, indicating that the
lectin domains were properly folded.
Anti-HIV cytopathicity assay
The mGRFT tandemers, as well as mGRFT and GRFT,
were tested simultaneously in a whole-cell anti-HIV
assay that measures HIV-1RF-induced cytopathicity in
the T-lymphoblastic cell line CEM-SS. This assay also
tests for compound-induced cytotoxicity to uninfected
CEM-SS cells. The results (Table 1) showed that, as re-
ported previously, mGRFT was significantly weaker than
GRFT, with an EC50 value of 119.3 nM. For the mGRFT
tandemers, 2mGRFT (EC50 = 2.7 pM) and 2mGRFT3
(EC50 = 2.6 pM) were 5-fold more active than GRFT
(EC50 = 13.8 pM). The antiviral activity displayed by
the 3mGRFT tandemer was enhanced by another 5
fold, with an EC50 = 1.0 pM. However, no furtherFigure 2 Theoretical structures of GRFT-tandemers. Griffithsin tandeme
of monomeric units attached by flexible linker regions. The N and C termin
approximately 10 Å apart, causing the individual domains in the tandemer
10 Å long in its extended conformation.enhancement of antiviral activity was observed for
constructs with additional mGRFT domains, since the
anti-HIV activity of 4mGRFT (EC50 = 1.2 pM) was
similar to 3mGRFT. The similar anti-HIV activity of
2mGRFT and 2mGRFT3 indicated that the longer
interdomain linker did not affect the potency of the
tandemers. None of the mGRFT tandemers displayed
any toxicity to the CEM-SS cells at the highest tested
doses (see Additional file 2: Figure S1).
Single cycle pseudo-HIV-1 virus neutralization assay
All mGRFT tandemers as well as mGRFT and native di-
meric GRFT were tested for their activity against a
spectrum of HIV-1 strains from different subtypes in a
Tzm-bl single cycle neutralization assay system. As
expected, the activity of all GRFT molecules tested was
reduced when compared to the multiple cycle HIV-1
induced cytopathicity assay. The results, as shown in
Table 2, indicate that the 3mGRFT and 4mGRFT tande-
mers were, on average, more potent than native dimeric
GRFT, whereas the 2mGRFT and 2mGRFT3 tandemers
were not significantly better than native dimeric GRFT.
Strikingly, two viral strains, subtype B CAAN5342.2 and
subtype C CAP206.8 were shown to be resistant to
native dimeric GRFT but retained sensitivity to the
3mGRFT and 4mGRFT tandemers, with the 3mGRFT
and 4mGRFT tandemers at least 10-fold more active
than native dimeric GRFT. A similar result was also seen
with the subtype A virus Q168.a2 which was also ~10rs 2mGRFT, 2mGRFT3, 3mGRFT, and 4mGRFT are shown as models
i (red and black, respectively) in a single mGRFT domain are
s to branch out. Each Gly-Thr-Gly linker (blue) is also approximately
Table 1 Physical characteristics an anti-HIV activity of griffithsin tandemers
Name Number of domains Linker Molecular Weight (kDa) Anti-HIV EC50
1 (pM) Terminal binding
surface distance (Å)
GRFT 2 none 25.6 13.8 ± 0.3 50
mGRFT (1GS-S [30]) 1 none 12.8 119,300 ± 19,300 n.a.
2mGRFT 2 Gly-Thr-Gly 25.8 2.7 ± 2.7 70
2mGRFT3 2 (Gly-Thr-Gly)3 26.2 2.6 ± 5.3 90
3mGRFT 3 Gly-Thr-Gly 38.8 1.0 ± 2.9 90
4mGRFT 4 Gly-Thr-Gly 51.8 1.2 ± 0.3 100
1Effective concentration at which 50% of CEM-SS cells are protected from the cytopathic effects of HIV-1RF infection.
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tandemers.
To evaluate the role of specific oligosaccharides in
the sensitivity of subtype B CAAN5342.2 and subtype
C CAP206.8 to wild type dimeric GRFT compared to
the 3mGRFT and 4mGRFT tandemers we undertook
to restore two specific oligosaccharide attachment
sites on gp120 into these Env constructs by mutating
specific residues at positions 234 N and 295 N. As can
be seen in Figure 3, insertion of these two oligosac-
charide attachment sites restored sensitivity to native
dimeric GRFT (as well as the 2mGRFT and 2mGRFT3
tademers) but did not significantly affect the activity




















Median 4.41 6.22Isothermal titration calorimetry
Isothermal titration calorimetry was used to characterize
the thermodynamics of binding of the mGRFT tande-
mers to the HIV envelope glycoprotein gp120, as shown
previously with GRFT [14]. Since 4mGRFT exhibited no
better activity than 3mGRFT in anti-HIV assays, it was
not investigated further. The gp120 binding of 2mGRFT,
2mGRFT3, and 3mGRFT was fully characterized and
the thermodynamic parameters of the interactions are
detailed in Table 3. Binding of gp120 to the mGRFT tan-
demers was revealed to be exothermic in nature. The
exothermic heats of interaction (negative ΔH values;
Table 2) were likely due to polar and electrostatic interac-
















Figure 3 Effect of the addition of glycans at positions 234 N and 295 N on HIV-1 sensitivity to GRFT and mGRFT-tandemers. Pseudoviruses
from either (A) HIV-1 CAAN5342.A2 or (B) HIV-1 CAP206.8 bearing either wild-type gp120 (black bars) or re-engineered mutant gp120 restoring the glycosylation
sites at position 234 and 295 (white bars) were tested for their sensitivity to native GRFT or mGRFT tandemers. Anti-HIV activity was visualized using the
single-cycle Tzm-bl assay system with activity reported as the effective concentration that inhibited infection by 50% (EC50). All experiments
were done in triplicate with the average value reported. Numbers in red indicate fold-difference in EC50 values between wild-type and mutant
gp120 bearing pseudoviruses.
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binding between GRFT and high-mannose oligosacharides
[30], an enthalpy-entropy compensation was apparent, in-
dicating that the favorable binding contacts between
GRFT and gp120 had overcome the unfavorable conform-
ational penalties of the bound partners and the unfavor-
able entropy of water (negative TΔS values; Table 3) at the
interface and around the bound complex, resulting in
energetically-favored binding with gp120 (negative ΔG
values; Table 3).
The observed tight, nanomolar binding affinities were
close to the accuracy limits of the calorimetric instru-
ment but well within the experimental error and the cal-
culated Kd values (Table 3), showed that the mGRFT
tandemers bound gp120 with slightly stronger affinity
than GRFT. Particularly in the case of the 2mGRFT3
and 3mGRFT constructs, a 3 nM Kd value was calcu-
lated for both tandemers. Deconstruction of the gp120
binding affinities into their respective enthalpic and en-
tropic contributions provided further insight into the na-
ture of the binding between the mGRFT tandemers and
gp120. From an examination of the enthalpy of binding
(ΔH) it was clear that the mGRFT tandemers mediated
a higher number of binding contacts with gp120 than
did GRFT (Table 3).
The enthalpy of binding was, however, not the sole de-
terminant of an optimal binding interaction. AlthoughTable 3 Thermodynamic parameters of griffithsin binding to
Affinity (μM) ΔH (kcal/mol)
GRFT 0.008 ± 0.004 – 30.4 + 0.3
mGRFT 0.112 ± 0.050 – 35.5 + 0.6
2mGRFT 0.005 ± 0.002 – 69.6 + 0.5
2mGRFT3 0.003 ± 0.001 – 47.2 + 0.6
3mGRFT 0.003 ± 0.001 – 74.4 + 0.42mGRFT and 3mGRFT binding events were the most
exothermic, the 2mGRFT3 construct produced the best
overall binding profile among the mGRFT tandemers,
showing very little entropic cost for binding (TΔS = −
35 kcal/mol). The enthalpy/entropy compensation (ΔH/
ΔS) ratio for 2mGRFT3 was 1.33, compared to 1.16 and
1.19 for 2mGRFT and 3mGRFT, respectively (Table 3).
As with any tethered constructs, the crosslinking inter-
actions with gp120 and formation of water filled aggre-
gates would be entropically disfavored, primarily due to
the decreased entropy of the “caged” water molecules
within the crosslinked complexes [31]. It was clear from
the enthalpy-entropy compensation that the mGRFT
tandemers either did not form large aggregates with
gp120, or if they did, the crosslinked complexes were
soluble and flexible enough to prevent any great degree
of trapping of the solvent water molecules. The gp120 ti-
trated solutions of the mGRFT tandemers were far less
cloudy than the post-titration solution of GRFT, suggest-
ing that little or no crosslinked aggregation had taken
place. In particular, solution of the 2mGRFT3 complex
with gp120 was essentially clear.
Dynamic light scattering
One of the common attributes of many lectins is their
capacity to agglutinate pathogens [32]. Although anti-
viral lectins such as GRFT have been shown not toHIV-1 gp120
ΔG TΔS ΔH/TΔS
– 11.2 ± 0.3 – 19.2 ± 0.3 1.58
– 9.5 ± 0.7 – 26.0 ± 0.7 1.36
– 11.6 ± 0.6 – 59.9 ± 0.5 1.16
– 11.8 ± 0.2 – 35.4 ± 0.6 1.33
– 11.8 ± 0.2 – 62.7 ± 0.4 1.19
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these lectins, which contain multiple binding domains,
aggregate viruses [30]. To determine if this was true and
to evaluate the role that the enhanced flexibility in bind-
ing domains may play in this phenomenon, we used
dynamic light scattering to measure the aggregation of
HIV-1BAL virions after treatment with mGRFT, GRFT, or
one of the four GRFT tandemers. As shown in Figure 4,
GRFT did aggregate HIV-1BAL virions to a significant ex-
tent when compared to untreated virions. As expected,
mGRFT, with only a single binding domain, did not ag-
gregate virions but, interestingly, also none of the GRFT
tandemers, including 4mGRFT with its four binding do-
mains, caused virions to aggregate.
Cryo-electron microscopy
The interactions of GRFT, mGRFT, and the tandemers
with purified HIV-1BaL virions were evaluated using
cryo-electron microscopy. The control experiments with
HIV-1Bal in the absence of any lectins showed a uniform
distribution of virions in the imaging field, with virions
having approximately 100 nm diameter and spherical
shape (Figure 5A). Ten-nanometer gold fiducials appear
as electron dense spots in the micrographs. When virions
were imaged at high magnification with cryo-electron
tomography, individual envelope glycoprotein spikes were
visible (Figures 5B, C, red arrows). The spikes were of the
expected height of ~ 120 Å as measured from the mem-
brane, with a structural profile consistent with previous
electron tomographic studies [33-38].Figure 4 Results of dynamic light scattering experiments on
HIV-1BAL virions treated with GRFT, mGRFT, or the mGRFT
tandemers. Dynamic light scattering traces are shown for HIV-1BAL
viruses without lectin, with mGRFT, with GRFT, or with one of the
tandemers. Negative controls with buffers or purified lectin did not
measurably scatter light.The overall spatial distribution and shape of the vi-
rions in the presence of mGRFT appeared similar to that
of the negative control (Figure 5D). However, differences
in spike size and structural profile were evident (Figure 5E
and F, red arrows). Viruses exposed to mGRFT displayed
an additional density on the spike that was irregular in
both shape and the degree of enlargement. The effect of
GRFT on HIV-1 differed dramatically from that of
mGRFT. Virions treated with GRFT formed large aggre-
gates having lateral dimensions on the micrometer scale
(Figure 5G). These aggregates appear in the micrograph as
large electron-dense swathes. Individual virions could be
identified at the periphery of the aggregates, and though
they seem to maintain their membrane integrity, their
shapes were highly distorted. Tomography revealed dense
masses of protein at the interfaces between virions
(Figures 5H and I), which consistently co-localized to the
interface between neighboring virions. The mGRFT tande-
mers displayed mutually similar effects on HIV-1 virions
and envelope glycoproteins (Figures 5J, K, I, and M, re-
spectively), but differed significantly from virions treated
with GRFT. Tomographic imaging showed that virions
treated with the mGRFT tandemers remained monodis-
perse, similar to the results with mGRFT and dissimilar
from GRFT.
Discussion
The functional unit of native GRFT is an obligate domain-
swapped homodimer [39], with two carbohydrate-binding
surfaces located at the opposite ends of the dimeric mol-
ecule. The first 15 residues of each monomer form a
strand-loop-strand structure that completes the β-prism-II
fold of the opposite monomer. Each β-prism harbors three
carbohydrate-binding sites on one of the terminal facets of
the prism. The centers of the carbohydrate-binding sites
form an equilateral triangle with 15 Å sides. The domains
are oriented at a ~160° angle from each other, with the
centers of the triangular carbohydrate-binding surfaces
positioned 50 Å apart (Figure 1A). The orientation of the
domains is fixed, since the dimer is formed by domain
swapping involving two β strands, resulting in a rigid mol-
ecule [26-28] The three carbohydrate-binding sites on the
surface of each domain act as a selective mechanism for
specifically targeting high-mannose, branched carbohydrate
environments typically found on viral envelope glycopro-
teins [40]. Viral glycoproteins present a preponderance of
high mannose oligosaccharides when compared to human
cellular glycoproteins, which have a larger proportion of
sialylated oligosaccharides. Alignments of glycans identified
on gp120 in vitro [6,41] with N-linked sequon variations of
gp120 identified in silico suggests that high-mannose modi-
fications dominate the conserved regions of gp120 [11].
The mGRFT tandemers described here were designed
to evaluate the role of the fixed spatial orientation of
Figure 5 (See legend on next page.)
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Figure 5 Electron micrographs of the HIV-1 virions interacting with different constructs of GRFT-based lectins. (A) Projection of
untreated HIV-1 virions. Virions are observed as ~ 100 nm circles in the imaging field which includes 10-nanometer-sized protein-A gold fiducials
which appear as dark spots. (B, C) Slices through tomograms of untreated HIV-1 virions with red arrows indicating individual Env proteins. (D)
Projection of HIV-1 virions that were incubated with mGRFT prior to vitrification. (E, F) Slices through tomograms of HIV-1 virions treated with
mGRFT. Representative Env glycoprotein spikes are indicated by red arrows (E). A patch of glycoprotein spikes is indicated by a red arc (F). (G)
Projection of HIV-1 virions that were incubated with native GRFT prior to vitrification. (H, I) Slices through tomograms of virions at the periphery
of the aggregates in virions treated with native GRFT. (J–M) Slices through tomograms collected from vitreous preparations of HIV-1 virions with
GRFT tandemer constructs, 2mGRFT (J), 2mGRFT3 (K), 3mGRFT (I), and 4mGRFT (M). Scale bars are 500 nm in panels (A, D, and G) and 50 nm in
the remaining panels.
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flexibility in the linker region of the mGRFT tandemer
structures we enhanced the ability of the second
mGRFT bining site to sample the local oligosaccharide
environment on individual virions. The larger mGRFT
tandemers (2mGRFT3, 3mGRFT and 4mGRFT) also in-
creased the distance between the individual mGRFT
binding domains, thus increasing the potential scope of
GRFT-oligosaccharide interactions to distances greater
than 50 Å.
All of the designed mGRFT tandemers were readily
expressed in E. coli and purified to homogeneity. The
mGRFT tandemers are distinct from other recently pub-
lished GRFT tandemer constructs [42] in that they were
created using obligate monomeric forms of GRFT [30],
thereby preventing any potential for domain swapping
by the expressed mGRFT tandemers. The maintenance
of the mGRFT form of individual lectin domains in the
mGRFT tandemers was confirmed by differential scan-
ning calorimetry which showed that mGRFT tandemers
melted at temperatures corresponding to mGRFT and
not native, dimeric GRFT (Additional file 1: Table S1).
Previous calorimetric evaluations of the binding of
high-mannose oligosaccharides by GRFT [14,18,30] and
our present data on the binding of the mGRFT tande-
mers to gp120 showed an overall similar mode of inter-
action, primarily involving favorable polar-electrostatic
contacts. Clear differences among the antiviral proteins
were evident, however, when the bindings were parsed
into individual thermodynamic contributions (Table 3).
The data suggested that steric hindrance and/or lack of
flexibility in GRFT appeared to hamper its domains from
making full contact with gp120, whereas the flexible
linkers in the GRFT tandemer structures allowed their
mGRFT domains to sample more extensively the gp120
surface glycans (comparing ΔH values in Table 3).
The mGRFT constructed in our previous work dis-
played a large reduction in its anti-HIV activity in the
CEM-SS HIV-1-induced cytotoxicity assay system. It is
important to note that, whereas mGRFT was far less ac-
tive than GRFT, its anti-HIV activity was still in the
nanomolar range [30]. The mGRFT tandemers created
for this study all showed anti-HIV activity significantly
better than mGRFT and five- to ten-fold better thannative, dimeric GRFT in the same assay system (Table 1).
We also tested the mGRFT tandemers in a TzmBl single
cycle pseudovirus assay system against several different
strains of HIV-1 to assess their broader activity com-
pared to both mGRFT and native GRFT. The results
showed that the 3mGRFT and 4mGRFT tandemers had
better overall anti-HIV activity than wild-type GRFT
with significant strain variance in EC50 values (Table 2).
The data also showed that the 3mGRFT and 4mGRFT
tandemers retained activity against strains of virus which
displayed a level of resistance to native dimeric GRFT.
We evaluated the data to determine whether or not in-
creasing the length of inter-domain linkers would affect
anti-HIV activity. The maximum theoretical distance be-
tween the terminal carbohydrate-binding surfaces of
each mGRFT tandemer was calculated based on basic
models derived from the X-ray crystal structure of
mGRFT (Table 1, Figure 2). In native GRFT the distance
between the centers of the carbohydrate-binding regions
on each domain was ~50 Å (Figure 1A). Increasing the
linear length of the mGRFT tandemers from ~70 Å
(2mGRFT) to ~90 Å (2mGRFT3) resulted in a nearly
identical or slightly worse anti-HIV activity overall, sug-
gesting that this increase in potential distance between
mGRFT domains was not a determining factor in anti-
HIV potency. Increasing the number of mGRFT do-
mains did enhance antiviral activity. However, this effect
was limited to three mGRFT domains as evidenced from
the nearly identical anti-HIV activities of 3mGRFT and
4mGRFT (Tables 1 and 2). The limit on the number of
mGRFT domains was possibly due to geometric con-
straints that could limit access to glycan ligands by the
fourth mGRFT domain of 4mGRFT and/or saturation of
local viral oligosaccharides with mGRFT domains.
The anti-HIV activity of mGRFT tandemers does not
stem from aggregation of virions, as evidenced by the
absence of virion agglutination in dynamic light scatter-
ing experiments (Figure 4). In contrast, native GRFT
binding to HIV-1 resulted in extensive aggregation of vi-
rions (Figure 4). The dimeric structure of native GRFT
enhanced its anti-HIV activity by orders of magnitude
but also led to viral aggregation. While this aggregation
is a possible contributing factor to the antiviral activity
of native GRFT, the ability to cause aggregation is clearly
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the mGRFT tandemers. This was evident from both the
electron microscopy and light scattering results for HIV
treated with the four tandemers. All tandemers were
equally or more active than GRFT but none of the
mGRFT tandemers caused aggregation of HIV virions.
The inability of the mGRFT tandemers to cause viral
aggregation likely stems from the conformational flexi-
bility of the linkers between the mGRFT domains. In na-
tive GRFT the two domains are rigidly held across from
each other. When one domain of GRFT binds to an Env
spike, the second domain would be oriented away at a
~160° angle from that spike and is likely more available
for binding the glycans on other Env spikes as well as
the glycans on the same spike. In the case of the mGRFT
tandemers, after binding of the first mGRFT domain to
an Env spike, the flexible linkers would allow the
remaining mGRFT domains to more readily sample the
local environment and bind to the nearest available
carbohydrate ligand. The local concentration of ligands
available for subsequent mGRFT domains is potentially
higher on the same spike than in the overall solution.
Therefore, the mGRFT tandemers, owing to the flexibil-
ity of their linkers, are more likely to bind glycans on
the same virion, whereas native GRFT, due to its con-
formational rigidity, would more favor inter-virion cross-
linking.
These observations have implications for understand-
ing the mechanism whereby the mGRFT tandemers
neutralize HIV. The antiviral activity of GRFT, mGRFT,
and the mGRFT tandemers stems from their selective
binding to high mannose oligosaccharides on Env spikes.
Natural mutations that removed glycosylation at posi-
tions Asn234 and Asn295 have been reported to impart
resistance to GRFT [43]. In addition, Huang et al.
showed that deglycosylation of gp120 at Asn295 or
Asn448 also resulted in resistance to GRFT [44]. The lo-
cation of these oligosaccharide attachment sites on
gp120 are shown in Figure 6. To investigate the role of
specific oligosaccharides in the sensitivity to GRFT tan-
demers, we utilized genetically-engineered pseudotype
viruses including either HIV-1 clade B CAAN5342
gp120 (Figure 3A) or clade C CAP206.8 gp120 (Figure 3B)
sequences. We tested both strains in either the presence
or absence of oligosaccharide attachment sites at positions
234 N and 295 N of the gp120 protein. Figure 3 displays
the results of our assessment of the activity of either
wild-type GRFT, mGRFT, or mGRFT tandemers against
these viruses. The 3mGRFT and 4mGRFT tandemers
retain significantly more activity against wild-type GRFT-
resistant viruses than the 2mGRFT, 2mGRFT3, or
wild-type GRFT. We speculate that this increased ac-
tivity against resistant viruses is due to the ability of
these larger mGRFT tandemers to sample a broaderrange of oligosaccharides on gp120 than the smaller
mGRFT tandemers or the conformationally-restricted
wild-type GRFT.
Mapping the location of the Asn234, Asn295, and
Asn448 glycans on trimeric spike structures (Figure 6)
suggests that glycans decorating these asparagines are
located on the lateral edges of HIV spikes. The ar-
rangement of the griffithsin monomers in the mGRFT
tandemers is such that they are able to bind carbohy-
drate moieties on the same virion, but not in a way
that bridges separate virions, as demonstrated by the
tomographic and light scattering experiments. Given
the molecular dimensions of the mGRFT tandemers
(<100 Å across), and the fact that neighboring spikes
on the virus are spaced apart by significantly greater
and variable distances (each trimeric Env itself is ~
150 Å across), it follows that the multiple sites on the
mGRFT tandemers are occupied by carbohydrates that
are displayed within the same Env trimer, with a high
likelihood of crosslinking across protomers within the
trimer. Cryo-electron microscopic studies have shown
that CD4-induced opening of the trimeric Env spike is
necessary for exposure of gp41 that initiates the first
step in the fusion of viral and target cell membranes
[34,36,46]. The crosslinking of gp120 protomers may
essentially block the opening of the trimeric spike and
prevent exposure of gp41 and its fusogenic components
required for viral entry, thus providing a likely mechanism
for the potent function of GRFT and mGRFT tandemers
as antiviral agents.
Conclusion
The mGRFT tandemers display picomolar anti-HIV
activity and, unlike native GRFT, do not aggregate
viral particles. mGRFT tandemers also retain potency
against viruses resistant to native GRFT. The data
presented here demonstrate the potential utility of
mGRFT tandemers for the microbicide development,
as well as highlight the complex spatial and orientation
requirements for viral neutralization by carbohydrate-
binding agents such as griffithsin. The 3mGRFTand
4mGRFT tandemers display some advantages over na-
tive GRFT (e.g. activity against GRFT-resistant viruses)
but the addition of flexible linkers makes these con-
structs more susceptible to proteolytic degradation
and less thermally stable. The advantages or disadvan-
tages of the absence of viral aggregation by mGRFT
tandemers, though perhaps responsible for their mod-
erately improved in vitro activity, is of undetermined
value in an in vivo setting. Further studies on the full
physiological and immunological consequences of
mGRFT tandemer administration will be necessary to
fully evaluate the potential of these engineered lectins
for microbicide development.
Figure 6 Location of GRFT binding-associated oligosaccharides (coupled to Asn234, Asn295, and Asn448) in the context of HIV trimeric
spike. Disaccharide modification of Asn234 (blue), Asn295 (red) and Asn448 (yellow) are displayed on a gp120 trimer. X-ray crystal structure of the
partially glycosylated HIV-1HXBc2 gp120 (PDB 1GC1 [45]) was superimposed on unliganded gp120 electron tomography structure (PDB 3DNN [34]).
Moulaei et al. Retrovirology  (2015) 12:6 Page 10 of 14Methods
Cloning, expression and purification of GRFT, mGRFT and
mGRFT tandemers
All restriction enzymes were purchased from New England
Biolabs. All chemicals were obtained from American
Bioanalytical, unless otherwise stated. All primers were pur-
chased from Integrated DNA Technologies. Protein purifi-
cation was performed as described previously for the
monomeric forms of GRFT [32], except that buffer A con-
tained 50 mM maltose.
Construction of plasmid p420TG and p2mGRFT
For the construction of the mGRFT tandemers we chose a
construct (1GS-S) that, as reported previously [30], pro-
duced obligate monomeric GRFT. An expression vector
containing the gene for 1GS-S (see Ref. [30] for nomencla-
ture of the different constructs of mGRFT) downstream ofa TEV protease cleavage site [30] was used as a template
to amplify a second 1GS-S cassette using standard PCR
protocols and PfuUltra® Hotstart PCR Master Mix (Strata-
gene). The amplified cassette contained only the 1GS-S
gene terminated with a stop codon and flanked by two
XhoI restriction endonuclease sites. The amplified 1GS-S
cassette was inserted at the XhoI site downstream of the
first 1GS-S cassette in the original expression vector used
as a template. The correct orientation of the second cas-
sette was verified by sequencing. Site-directed mutagenesis
was used to mutate the DNA sequence between the two
1GS-S cassettes to 5’-ggtaccgcgggctagcatatgtcgaccggt-3’,
removing the stop codon at the 3’-terminus of the first
1GS-S cassette and introducing a new multiple-cloning
site (MCS) with flanking KpnI and AgeI sites (p420TG).
In order to create an expression plasmid for 2mGRFT
(p2mGRFT), site-directed mutagenesis was used to alter
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tor contained a single ORF expressing two 1GS-S domains
preceded by a TEV protease cleavage site and linked by a
GlyThrGly linker.
Construction of plasmids p3mGRFT, p4mGRFT, and
p2mGRFTlong
Primers 5’- ggaccggtgccgtactgttcatagtagatgtccaggctatc-3’
and 5’-ggggtaccggcagctcgacccatcgcaag-3’ were used with
p2mGRFT as the template in a standard PCR reaction.
Two amplicons corresponding to single and double
1GS-S cassettes were separated and purified from an
agarose gel. Each amplicon contained a KpnI site
followed by a glycine codon (ggc) at the 5’ terminus
and the same glycine codon followed by a AgeI site at
the 3’ terminus.
The single and double 1GS-S cassettes were ligated in
between the KpnI and AgeI sites in p420TG to yield
p3mGRFT and p4mGRFT, respectively. Site-directed
mutagenesis was used to alter the GlyThrGly linker in
p2mGRFT to a GlyThrGlyGlyThrGlyGlyThrGly linker,
yielding p2mGRFT3 for expression of 2mGRFT3. The
complete DNA and amino acid sequences of the GRFT
tandemers are included in Additional file 3.
Purification protocol for tandemers
All tandemers used in the experiments outlined in this
paper were purified generally as described previously for
the monomeric forms of GRFT [30], except that the cell
lysis buffer contained 50 mM maltose to improve recov-
ery. Briefly, cells were lysed in 50 mM Tris (pH 8.0),
200 mM NaCl, 50 mM maltose and 5% v/v BugBuster
10x Protein Extraction Reagent (Merck), with continu-
ous stirring at room temperature overnight. The lysate
was then purified by either (i) heating at 50°C for 10 mi-
nutes, (ii) adjusting the buffer to 15% v/v ethanol, or (iii)
adjusting the buffer to 10% v/v isopropanol. The lysate
was centrifuged at 17,000 rpm in a SS-34 rotor for
30 min. The supernatant was loaded onto a Ni-NTA
Superflow column (QIAGEN), equilibrated with five
column volumes of buffer A (20 mM Tris [pH 8.0],
200 mM NaCl). The column was washed with buffer A
and eluted with buffer A containing 250 mM imidazole.
TEV protease was added in 1:100 molar ratio of protease
to eluted protein and the sample was incubated at room
temperature for 1 hr. The TEV-digested sample was then
passed over the same Ni-NTA Superflow column equili-
brated with five column volumes of buffer A. The flow-
through was collected. For further purification the
pooled fractions were loaded onto an amylose column
(New England Biolabs) equilibrated with five column
volumes of buffer A. The column was washed with buffer
A and eluted with buffer A additionally containing 50 mM
maltose. The pooled fractions containing tandemers werethen dialyzed against pure deionized water, or against
20 mM Tris (pH 8.0), 100 mM NaCl. All purification pro-
cedures were performed at room temperature. As with the
native GRFT, the GRFT tandemers were all stable to pH
ranges from 1–8 and to both heat (up to 50°C) and or-
ganic solvents (i.e. alcohols, acetonitrile).
Differential scanning calorimetry
Differential scanning calorimetry (DSC) experiments
were carried out with a Microcal VP-DSC microcalorim-
eter (Microcal, Northampton, MA). The concentrations
of all tandemer proteins were determined by amino acid
analysis, and a 60 μM concentrated sample of a tande-
mer protein was evaluated per experiment. By routine
protocol, buffer (50 mM Tris, 60 mM NaCl) was intro-
duced to both the reference and sample cells and the
calorimeter was allowed to ramp through one cycle of a
heat-cool cycle (10°C to 90°C) at a heating/cooling rate
of 60°C/hr. During the down scan at 25°C, the buffer so-
lution from the sample cell was quickly and efficiently
replaced with a degassed tandemer protein sample. The
entire system was re-pressurized to approximately 30 psi
of positive pressure to prevent evaporation at higher
temperatures, and the experiment was allowed to con-
tinue. A total of 6 alternating up-down scans (10°C to
90°C) were performed to measure possible reversibility
of folding/unfolding of the tandemers. According to
manufacturing protocol, Origin DSC Analysis software
was used to correct for buffer effects and to carry out
the integration of the unfolding transitions of the tande-
mers. The baseline corrected thermograms were fitted
to a two-state melting model and the calorimetric transi-
tion enthalpy (ΔHunf ) was obtained from the area under
the excess heat capacity peak, the midpoint of the transi-
tion calculated as the melting temperature (Tm).
HIV-induced cytotoxicity bioassay
A 2,3-bis-[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazo-
lium-5-carboxanilide inner salt (XTT)-tetrazolium-based
assay was used to determine the anti-HIV activity of
mGRFT, GRFT, and mGRFT tandemers against HIV-1RF
challenged T-lymphoblastic CEM-SS cells, as described
previously [47]. XTT was graciously supplied by the
Drug Synthesis and Chemistry Branch, Developmental
Therapeutics Program, Division of Cancer Treatment
and Diagnosis, National Cancer Institute. CEM-SS cells
were maintained in RPMI 1640 media without phenol
red and supplemented with 5% fetal bovine serum
(BioWhittaker), 2 mM L-glutamine (BioWhittaker),
and 50 μg/ml gentamicin (BioWhittaker) (complete
medium). Exponentially growing cells were washed
and resuspended in complete medium, and a 50 μl ali-
quot containing 5 × 103 cells was added to individual
wells of a 96-well round-bottom microtiter plate containing
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mers (2mGRFT, 2mGRFT3, 3mGRFT, 4mGRFT) in a vol-
ume of 100 μl of medium. Stock supernatants of HIV-1RF
were diluted in complete medium to yield sufficient cyto-
pathicity (80–90% cell kill in 6 days), and a 50 μl aliquot
was added to appropriate wells. Plates were incubated for
6 days at 37°C and then stained for cellular viability using
XTT. All experiments were performed in triplicate. To as-
sess activity EC50 values were determined by calculating the
point at which the dose–response sigmoid curve of increas-
ing cell-survival crossed the point at which 50% of the cells
survived. Compound-induced direct cytotoxicity to CEM-
SS cells was tested simultaneously by adding identical con-
centrations of test compounds to wells containing only
CEM-SS cells and no virus. Cell viability in these wells was
measured at the same time point and by the same method-
ology as employed for wells used to evaluate the protection
against-HIV-1-induced cytopathicity.
Single-cycle Tzm-bl HIV-1 pseudovirus assay
The single-cycle pseudovirus assay was performed as
previously reported using virus strains as described in
Alexandre et al. [43]. Briefly, HIV-1 psudoviruses were
generated using pSG3ΔEnv plasmids, which were co-
transfected with various Env from different virus strains
into 293 T cells using the Fugene transfection reagent
(Roche Applied Sciences, Indianapolis, IN).
The single cycle pseudovirus neutralization assay was
performed in a manner similar to that previously re-
ported by Montefiori [48]. Briefly, various dilutions of
each compound (GRFT, mGRFT, or mGRFT tandemers)
were added to 100 μL of DMEM media augmented with
10% FBS in individual wells of a 96-well plate. To each
test well 200 TCID50 of pseudovirus in 50 μL of media
was added an incubated for 1 hr at 37°C. Then, 100 μL
of TZM-bl cells at a concentration of 1×105 cells/mL
was added and cultured at 37°C for an additional 48 hrs.
Viral infections were visualized by measuring the activity
of firefly luciferase. Inhibitory concentrations (IC50) were
calculated as the concentration resulting in a 50% reduc-
tion of relative light units (RLU) compared to virus con-
trols. All measurements were performed in triplicate.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments were
performed on a Microcal VP-ITC microcalorimeter
(MicroCal, Northampton, MA). In a typical experiment
with the mGRFT tandemers and monomeric, glycosyl-
ated, bacculovirus-produced HIV-1IIIB gp120 (Immuno-
diagnostics, Inc., Woburn, MA), the mGRFT tandemer
protein (180 μM) was placed in the syringe injector and
the gp120 was placed in the calorimeter cell (2.5 μM). In
all experiments, a total of 55 injections of tandemer
(5 μl/injection) were made, with 600 s spacing betweeninjections. The titrations were all done in a rapidly stir-
ring solution (300 rpm) held at a constant temperature
of 30°C. The heats of binding were recorded as the ex-
cess power compensation required for maintaining the
same temperature during the course of the titration.
Baseline experiments of tandemer titration into buffer
were done to calculate heats of dilution and this value
was subtracted from the experimental heats of binding.
The resulting isotherms were fitted using Origin 5.0
nonlinear least-squares program according to manufac-
turer’s protocol, and the values for the enthalpy of bind-
ing (ΔH) and the dissociation constant were obtained.
From the dissociation constant, a value for the free en-
ergy of binding (ΔG) was extrapolated (ΔG = −RTlnKa),
and from this value, the entropy of binding (ΔS) was
lastly calculated (ΔG=ΔH –TΔS).
Dynamic light scattering
Whole HIV-1 viruses (AIDS and Cancer Virus Program,
Leidos Inc., Frederick National Laboratory for Cancer
Research, Frederick, MD 21702, USA) at stock concen-
tration (~ 1011 virions/mL) were diluted 1,000-fold in di-
lution buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA,
pH 7.4), and 1 mL of this diluted virus volume was
transferred to a plastic cuvette. Autocorrelation mea-
surements were carried out at 25°C using a DynaPro
NanoStar instrument (Wyatt Technology, Santa Barbara,
CA 93117, USA) that provided particle size distributions,
the peak of which was taken to be the mean particle size.
For dynamic light scattering (DLS) experiments, the vi-
ruses were pre-mixed with lectin at the same concentra-
tions used in cryo-electron microscopy experiments.
This ensured a valid comparison between dynamic light
scattering experiments, and the imaging experiments in
which there was no sample dilution before mixing. Dy-
namic light scattering measurements were carried out
with the assistance from Dr. Grzegorz Piszczek (National
Institutes of Health, National Heart, Lung and Blood In-
stitute, Biophysics Facility, Bethesda, MD 20814, USA).
Cryo-electron microscopy
Imaging experiments used purified suspensions of HIV-
1BaL virions with estimated concentration of ~ 10
11 vi-
rions/mL (AIDS and Cancer Virus Program, Leidos Inc.,
Frederick National Laboratory for Cancer Research,
Frederick, MD 21702, USA). Prior to use, viruses were
inactivated with Aldrithiol-2 which preserves viral entry
capacity and antigenic integrity at levels similar to those
of untreated virus. Sample mixtures were prepared by
adding 10 nm protein-A gold colloid (Cell Microscopy
Center, Utrecht University, 3584 CH Utrecht, The
Netherlands) to virus suspension, followed by addition
of one of six griffithsin constructs and incubation at 4°C
for 30 min. All GRFT constructs were added to the
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spect to the griffithsin monomer. Two microliters of
sample mixture were applied to plasma cleaned carbon-
coated 200-mesh grids (Quantifoil Micro Tools, 07745
Jena, Germany) and immediately blotted and plunge fro-
zen using a Mark III Vitrobot (FEI Company, Hillsboro,
Oregon 97124, USA) maintained at 25°C and 100% humid-
ity. Data was collected on samples maintained at −193°C
using a Tecnai G2 Polara transmission electron microscopy
(FEI Company, Hillsboro, Oregon 97124, USA) operated at
200 kV and equipped with an energy-filter and 2 K x 2 K
post-energy filter CCD camera (Gatan Incorporated, Pleas-
anton, CA 94588, USA). Projections were acquired with a
10–20 e−/Å2 dose at 4.5 kX magnification with −70 μm
underfocus. Tilt series spanned an angular range of +/− 65°
with 2° tilt increments and were acquired at −2.5 μm
underfocus with a per-tilt dose of 1 – 2 e−/Å2. Tilt series
were aligned using RAPTOR as implemented in IMOD
[49,50], and tomograms were reconstructed using R-
weighted back projection as implemented in IMOD.
Additional files
Additional file 1: Table S1. Differential scanning calorimetry –
determination of the melting temperatures (Tm) of griffithsin tandemers.
Additional file 2: Figure S1. Dose-response curves for mGRFT tandemers
anti-HIV activity.
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